2260669-29-0
Chemical Structure
Stigmasterol-d5-1
Synonym(s): Stigmasterin-d5-1
- CAS No.: 2260669-29-0
- Formula:C29H43D5O
- Molecular Weight:417.72
IUPAC Name: (3S,8S,9S,10R,13R,14S,17R)-17-((2R,5S,E)-5-isopropylhept-3-en-2-yl-6,6,7,7,7-d5)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol
InChIKey: HCXVJBMSMIARIN-NTWICQSISA-N
SMILES: C[C@@]12[C@](CC[C@]2([H])[C@H](C)/C=C/[C@@H](C([2H])([2H])C([2H])([2H])[2H])C(C)C)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4(C(C[C@H](CC4)O)=CC3)C
Biological Activity: Stigmasterol-d5-1 is deuterium labeled Stigmasterol. Stigmasterol is a plant sterol which has been focused on the cholesterol-lowering activity and is valued as an anti-stiffness factor in the therapy of rheumatic diseases[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Stigmasterol-d5-1 | 99.90% | Stigmasterol-d5-1 is deuterium labeled Stigmasterol. Stigmasterol is a plant sterol which has been focused on the cholesterol-lowering activity and is valued as an anti-stiffness factor in the therapy of rheumatic diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Stigmasterol (Standard) | 97.35% | Stigmasterol (Standard) is the analytical standard of Stigmasterol (HY-N0131). This product is intended for research and analytical applications. Stigmasterol is a plant sterol which has been focused on the cholesterol-lowering activity and is valued as an anti-stiffness factor in the therapy of rheumatic diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Stigmasterol-d6 | 97.05% | Stigmasterol-d6 is deuterium-labeled Stigmasterol (HY-N0131). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Stigmasterol | 99.26% | Stigmasterol is an orally acitve, immunomodulatory agent with anti-inflammatory and neuroprotective effect, as well as able to cross the blood-brain barrier. Stigmasterol activates AMPK, which in turn inhibits NF-κB and NLRP3 signaling pathways, reduces microglia-mediated neuroinflammation, and alleviates cognitive impairment and Alzheimer's disease. Stigmasterol regulates M1/M2 polarization of microglia through the TLR4/ NF-κB pathway, thereby reducing neuropathic pain. Stigmasterol can be used for neurodegenerative diseases, inflammatory diseases, and pain management, among others. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
